Filing summary: AcelRx Pharmaceuticals, Inc. (10-Q, quarter ended March 31, 2023)
Entity note: The filing identifies the registrant as AcelRx Pharmaceuticals, Inc., not Talphera, Inc. It reports first-quarter 2023 results and was signed May 10, 2023.
Business context and reporting period
AcelRx described itself as a specialty pharmaceutical company developing therapies for medically supervised settings. Its continuing focus was Niyad and other nafamostat candidates, plus licensed ephedrine and phenylephrine prefilled-syringe candidates. DSUVIA/DZUVEO was classified as discontinued operations after the company agreed to sell the business to Alora; the sale closed April 3, 2023.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Continuing-operations revenue | No revenue reported in the presented continuing-operations results | DSUVIA-related revenue is presented as discontinued operations |
| Research and development expense | $1.0 million | $0.8 million; up 25% |
| Selling, general and administrative expense | $4.3 million | $4.1 million; up 4% |
| Loss from continuing operations | $0.1 million income | $4.6 million loss |
| Discontinued-operations loss | $8.2 million | $4.1 million |
| Net loss | $8.2 million; $0.75 per share | $8.7 million; $1.19 per share |
| Cash used in operating activities | $5.3 million | $8.9 million |
The small continuing-operations profit reflected primarily a $5.3 million non-cash gain from the reduction in fair value of warrant liabilities; it does not indicate operating profitability. The discontinued-operations loss included a $7.0 million impairment of assets held for sale and $1.1 million impairment of fixed assets, partly offset by a $1.1 million gain on lease termination. DSUVIA discontinued-operations revenue was $0.5 million versus $0.4 million in Q1 2022; cost of goods sold was $0.7 million versus $0.4 million.
At March 31, cash and cash equivalents were $13.4 million, down from $20.8 million in cash, cash equivalents, restricted cash and short-term investments at December 31, 2022. Total assets were $26.3 million and stockholders’ equity was $14.2 million. Current liabilities were $9.5 million, including $3.3 million of current debt; total liabilities were $12.1 million. The filing states that the company had an accumulated deficit of $434.0 million. No meaningful operating margin is reported for continuing operations, which had no reported revenue.
After quarter-end, AcelRx repaid Oxford Finance approximately $3.4 million and terminated the loan on April 3, leaving it debt-free under that facility. The filing nevertheless states that existing resources were insufficient to fund planned operations and that additional capital would be needed before the 12-month anniversary of the filing date; substantial doubt about the company’s ability to continue as a going concern remained.
Material changes and significant transactions
- DSUVIA divestiture: Alora acquired specified DSUVIA/DZUVEO assets and assumed related liabilities. AcelRx received approximately $2.7 million at closing from Alora and Aguettant, and is eligible for 15% of net sales to most customers, 75% of net sales to the U.S. Department of Defense, up to $116.5 million in sales milestones, and certain other consideration. These amounts are contingent on contractual terms and commercial performance.
- Share count: Common shares outstanding rose to 10,924,294 at March 31 from 8,243,680 at year-end, primarily reflecting exercise of 2,632,898 prefunded warrants. The filing’s share and per-share figures reflect a 1-for-20 reverse split in October 2022.
- Debt and supply arrangements: The Oxford loan was repaid after the DSUVIA closing. AcelRx also reported an April memorandum of understanding for exclusive nafamostat API supply outside Asia, subject to milestone payments and efforts to execute a longer-term supply agreement.
- Aguettant amendment: In connection with the closing, Aguettant paid AcelRx €1.5 million; the maximum sales-milestone payments under the prefilled-syringe agreement fell from $24 million to $21 million.
Outlook, risks, and unusual items
- Management said it was focused on obtaining Emergency Use Authorization for Niyad in 2023 and expected, if authorized, to begin commercialization while initiating a study toward full regulatory approval. The EUA request was submitted April 27, 2023, after quarter-end. The filing notes that the EUA pathway is premised on the COVID-19 public health emergency, which was scheduled to end May 11, 2023; regulatory prospects and commercial relevance are uncertain.
- Niyad’s IDE remained under FDA review, and AcelRx anticipated a PMA pathway for full U.S. approval. The company also planned development work for LTX-608 and preparation of NDAs for the ephedrine and phenylephrine prefilled syringes.
- Nasdaq notified the company on April 26 that its share price had failed to meet the $1 minimum bid-price requirement for 30 consecutive business days. The initial compliance period ran through October 23, 2023; delisting risk could impair liquidity and access to capital.
- AcelRx disclosed a previously identified material weakness in EPS accounting controls that had led to restatements of its Q2 and Q3 2022 financial statements. Remediation was ongoing; management said enhanced review supported fair presentation of the current filing’s financial statements.
- A securities class action and consolidated shareholder derivative litigation remained pending. The company said it could not estimate a reasonably possible loss; a hearing on the motion to dismiss the second amended class-action complaint was scheduled for May 25, 2023.
- Other key risks include continued cash burn and financing uncertainty, clinical and regulatory setbacks, reliance on third-party manufacturers and a limited nafamostat API supply, Alora’s ability to commercialize DSUVIA, and possible dilution from future financing. The filing provides no specific revenue or earnings guidance.
Important facts for investors to verify
- Confirm the issuer identity: this supplied 10-Q is filed by AcelRx Pharmaceuticals, Inc.; the request names Talphera, Inc.
- Track cash runway, financing actions, and whether management’s going-concern concerns have been alleviated.
- Check FDA decisions and timing for Niyad’s EUA, IDE, and planned registrational study, including the effect of the COVID-19 emergency’s end.
- Monitor DSUVIA sales, especially DoD orders, and whether Alora’s performance triggers royalties or milestones.
- Verify Nasdaq bid-price compliance, status of the EPS-control remediation, and developments in the pending litigation.